ConductScience.org, home

Paper32166314

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Mathur R and 13 others. Neuro Oncol, 2020. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Papers, record 32166314. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32166314

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
PubMed
Journal
Neuro Oncol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
3.09
iCite
Revised in PubMed
2021-09-18
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mathur RRadhika
2Zhang YYalan
3Grimmer MRMatthew R
4Hong CChibo
5Zhang MMichael
6Bollam SSaumya
7Petrecca KKevin
8Clarke JJennifer
9Berger MSMitchel S
10Phillips JJJoanna J
11Oberheim-Bush NANancy Ann
12Molinaro AMAnnette M
13Chang SMSusan M
14Costello JFJoseph F

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain NeoplasmsMajor topic
DNA Modification MethylasesMajor topic
DNA Repair EnzymesMajor topic
GliomaMajor topic
Tumor Suppressor ProteinsMajor topic
Antineoplastic Agents, Alkylating
DNA Methylation
Humans
Neoplasm Recurrence, Local
Temozolomide

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 CA151022NCI NIH HHSUnited StatesT32CA151022PubMed and NIHNIH RePORTER
R01 CA169316NCI NIH HHSUnited StatesR01CA169316PubMed and NIHNIH RePORTER
P50 CA097257NCI NIH HHSUnited StatesP50CA097257PubMed and NIHNIH RePORTER
T32 GM008568NIGMS NIH HHSUnited StatesT32GM008568PubMed and NIHNIH RePORTER
F32 CA239472NCI NIH HHSUnited StatesF32CA239472PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in32927482MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma.https://conductscience.org/library/papers/32927482

Source PubMed

Download CSV of comments and corrections

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110029064Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.Cancer Res1999https://conductscience.org/library/papers/10029064PubMed
224227677featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.Bioinformatics2014https://conductscience.org/library/papers/24227677PubMed
315758010MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl J Med2005https://conductscience.org/library/papers/15758010PubMed
427571885Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.Neuro Oncol2017https://conductscience.org/library/papers/27571885PubMed
512815001Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.Cancer Epidemiol Biomarkers Prev2003https://conductscience.org/library/papers/12815001PubMed
626927331Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.J Mol Diagn2016https://conductscience.org/library/papers/26927331PubMed
721148162The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma.Jpn J Clin Oncol2011https://conductscience.org/library/papers/21148162PubMed
827157931The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.Acta Neuropathol2016https://conductscience.org/library/papers/27157931PubMed
922810491
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Acta Neuropathol2012https://conductscience.org/library/papers/22810491PubMed
1025724300Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Acta Neuropathol2015https://conductscience.org/library/papers/25724300PubMed
1116632515Adjusting batch effects in microarray expression data using empirical Bayes methods.Biostatistics2007https://conductscience.org/library/papers/16632515PubMed
1220372840Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.Oncol Rep2010https://conductscience.org/library/papers/20372840PubMed
1320375111partDSA: deletion/substitution/addition algorithm for partitioning the covariate space in prediction.Bioinformatics2010https://conductscience.org/library/papers/20375111PubMed
1427001570Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.J Clin Oncol2016https://conductscience.org/library/papers/27001570PubMed
1519224763Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.Neuro Oncol2009https://conductscience.org/library/papers/19224763PubMed
1627270107Clonal evolution of glioblastoma under therapy.Nat Genet2016https://conductscience.org/library/papers/27270107PubMed
1731263031Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.Clin Cancer Res2019https://conductscience.org/library/papers/31263031PubMed
1825516281Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol2014https://conductscience.org/library/papers/25516281PubMed
1927686946Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.Lancet Oncol2016https://conductscience.org/library/papers/27686946PubMed
2027943684Treatment Strategies for Low-Grade Glioma in Adults.J Oncol Pract2016https://conductscience.org/library/papers/27943684PubMed

See all 49 referencesDownload CSV of references

Cited by59

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
42368494Ensemble Machine Learning Approaches Predict Survival in Lower-Grade Glioma Based on Glycosphingolipid Gene Expression and Metabolic Modeling.Comput Struct Biotechnol J2026https://conductscience.org/library/papers/42368494PubMed
42313202MGMT promoter methylation across glioma subtypes: biological relevance, treatment response, and survival outcomes.Mol Biol Rep2026https://conductscience.org/library/papers/42313202PubMed
42192542Integrin-binding sialoprotein as an extracellular matrix-associated independent prognostic biomarker in glioma.BMC Cancer2026https://conductscience.org/library/papers/42192542PubMed
42147219Case Report: Identification of rare H3-3A p.G35W variant in a case of adolescent tectal plate low-grade glioma.Front Oncol2026https://conductscience.org/library/papers/42147219PubMed
41838210GPR40 Attenuates Glioma TMZ-Resistance Through Ferroptosis Inhibition.Neurochem Res2026https://conductscience.org/library/papers/41838210PubMed
41462160Prognostic value of LPAR1 expression and methylation in low-grade gliomas: a meta-analysis of TCGA and CGGA datasets and functional validation.BMC Cancer2025https://conductscience.org/library/papers/41462160PubMed
40949165IDH mutant high-grade gliomas.Front Mol Neurosci2025https://conductscience.org/library/papers/40949165PubMed
40739045Predictive efficacy and role of 2HG in MGMT promoter methylation in gliomas: a retrospective study based on MRS and mediator variable analysis.Br J Cancer2025https://conductscience.org/library/papers/40739045PubMed
40041202Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.Neurooncol Adv2025https://conductscience.org/library/papers/40041202PubMed
39990688Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003-2023).Front Oncol2025https://conductscience.org/library/papers/39990688PubMed
39745907Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.Neuro Oncol2025https://conductscience.org/library/papers/39745907PubMed
39560080Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.Neuro Oncol2025https://conductscience.org/library/papers/39560080PubMed
39555702DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.Cancer Biol Ther2024https://conductscience.org/library/papers/39555702PubMed
39031395Analysis of glutathione Stransferase mu class 5 gene methylation as a prognostic indicator in low-grade gliomas.Technol Health Care2024https://conductscience.org/library/papers/39031395PubMed
38948079STAT3 drives the malignant progression of low-grade gliomas through modulating the expression of STAT1, FOXO1, and MYC.Front Mol Biosci2024https://conductscience.org/library/papers/38948079PubMed
38912846The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Neuro Oncol2024https://conductscience.org/library/papers/38912846PubMed
38690285Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.Front Immunol2024https://conductscience.org/library/papers/38690285PubMed
38438348Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma.Nat Commun2024https://conductscience.org/library/papers/38438348PubMed
38117484The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.Cancer Res2024https://conductscience.org/library/papers/38117484PubMed
37905107Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma.bioRxiv2023https://conductscience.org/library/papers/37905107PubMed

See all 59 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
MGMT4255PubTator's text mininghttps://conductscience.org/library/genes/4255NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32166314

GET https://conductscience.org/api/papers/v1/32166314/references?page=2